Home › Stem Cell Cures

Stem Cell Cures

News Story
7/8/2014
Posted by Mark Reback
StemCells Inc.’s board of directors now includes the former president of the California stem cell agency that gave the company $19.4 million in research funding. StemCells Inc., a Newark company developing stem cell-based therapies, said Monday Dr. Alan Trounson is joining its board of directors, noting that he previously oversaw “the...
News Story
7/8/2014
Posted by Mark Reback
The San Francisco Chronicle today carried a story on the appointment of Alan Trounson, former president of the $3 billion California stem cell agency, to the board of  StemCells, Inc., which has received $19.4 million from the research program. Trounson’s appointment came only seven days after he left state employment. Last year,...
News Story
7/7/2014
Posted by Mark Reback
In laboratories across California, scientists are racing to turn stem cells into therapies for some of the world's most debilitating illnesses from cancer to Alzheimer's. Many of those researchers have received funding from a unique source: California's stem cell agency. Created by voters a decade ago, the California Institute for...
News Story
1/31/2014
Posted by Mark Reback
WASHINGTON (Legal Newsline) — The U.S. Patent and Trademark Office, in a federal court filing this month, argues that a consumer group challenging a patent on stem cells does not have standing to appeal the agency’s review decision. “Except at the behest of a party with a concrete and particularized interest in the question...
News Story
1/6/2014
Posted by Mark Reback
As scientists get closer to using embryonic stem cells in new treatments for blindness, spinal cord injuries and heart disease, a U.S. legal debate could determine who profits from that research. Consumer Watchdog, a nonprofit advocacy group, wants an appeals court to invalidate a University of Wisconsin-Madison’s patent for stem cells...
News Story
8/1/2013
Posted by Mark Reback
Last month, Consumer Watchdog filed its opening brief in an appeal of a Board decision affirming the patentability of U.S. Patent No. 7,029,913, arguing that the claims of the '913 patent are invalid because they cover ineligible subject matter and were anticipated and obvious.  The appeal arises from an inter partes reexamination of the...
News Story
7/8/2013
Posted by Mark Reback
Two US public interest groups have asked a federal appeals court to hear a challenge of a patent over human embryonic stem cells (hESCs). Consumer Watchdog, a non-profit consumer advocacy organisation based in Santa Monica, California, along with lawyers from the Public Patent Foundation (PPF), lodged an appeal from a decision by the US Patent and...
News Story
7/3/2013
Posted by Mark Reback
Public interest groups that earlier unsuccessfully sought to remove embryonic stem cell patents held by the Wisconsin Alumni Research Foundation have asked a federal appeals court to reopen the case challenging one of the patents, which they say should be invalidated because of a recent U.S. Supreme Court ruling. Consumer Watchdog of Santa Monica...
News Story
7/3/2013
Posted by Mark Reback
A patent controlling use of human embryonic stem cells should be struck down, two consumer groups said in a legal appeal filed Tuesday. Promising therapies developed with these cells will be delayed from reaching patients if the patent remains intact, say researchers, including Jeanne Loring of The Scripps Research Institute and Gene Yeo of UC San...
News Release
7/2/2013
Posted by John M. Simpson
WASHINGTON, DC – Two public interest groups today asked a federal appeals court to invalidate a patent on human embryonic stem cells held by the Wisconsin Alumni Research Foundation (WARF) because the claimed “cell culture falls within the ‘product of nature’ exception” of what can be patented.   In a brief...